The use of corifollitropin alfa in overlapped doses, in a desogestrel-primed ovarian stimulation regimen, as a new protocol towards an extremely patient-friendly approach: a case report

Abstract

Financial support: none. Conflicts of interests: Bruno Ramalho de Carvalho declares that he has already received funds to participate in scientific events and as sponsored speaker on behalf of Organon/Merck Sharp & Dohme Corp, on the topics of contraception and controlled ovarian stimulation in assisted reproductive technologies. However, this case report was a personal initiative and was not funded.